Medicinal chemistry in drug discovery in big pharma: past, present and future

被引:58
作者
Campbell, Ian B. [1 ]
Macdonald, Simon J. F. [1 ]
Procopiou, Panayiotis A. [1 ]
机构
[1] GlaxoSmithKline Med Res Ctr, Gunnels Wood Rd, Stevenage SG1 2NY, Herts, England
关键词
MOLECULAR COMPLEXITY; CANDIDATES; DESIGN; INDUSTRY; TARGETS; PROTEIN; SOLUBILITY; COMPANIES; LIGANDS; RULE;
D O I
10.1016/j.drudis.2017.10.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The changes in synthetic and medicinal chemistry and related drug discovery science as practiced in big pharma over the past few decades are described. These have been predominantly driven by wider changes in society namely the computer, internet and globalisation. Thoughts about the future of medicinal chemistry are also discussed including sharing the risks and costs of drug discovery and the future of outsourcing. The continuing impact of access to substantial computing power and big data, the use of algorithms in data analysis and drug design are also presented. The next generation of medicinal chemists will communicate in ways that reflect social media and the results of constantly being connected to each other and data.
引用
收藏
页码:219 / 234
页数:16
相关论文
共 67 条
  • [1] Deep Learning Applications for Predicting Pharmacological Properties of Drugs and Drug Repurposing Using Transcriptomic Data
    Aliper, Alexander
    Plis, Sergey
    Artemov, Artem
    Ulloa, Alvaro
    Mamoshina, Polina
    Zhavoronkov, Alex
    [J]. MOLECULAR PHARMACEUTICS, 2016, 13 (07) : 2524 - 2530
  • [2] Where will we get the next generation of medicinal chemists?
    Allen, Dave
    [J]. DRUG DISCOVERY TODAY, 2016, 21 (05) : 704 - 706
  • [3] [Anonymous], 2017, CHEM ENG NEWS, V95, P2
  • [4] [Anonymous], CHEM ENG NEWS
  • [5] The promise and peril of chemical probes
    Arrowsmith, Cheryl H.
    Audia, James E.
    Austin, Christopher
    Baell, Jonathan
    Bennett, Jonathan
    Blagg, Julian
    Bountra, Chas
    Brennan, Paul E.
    Brown, Peter J.
    Bunnage, Mark E.
    Buser-Doepner, Carolyn
    Campbell, Robert M.
    Carter, Adrian J.
    Cohen, Philip
    Copeland, Robert A.
    Cravatt, Ben
    Dahlin, Jayme L.
    Dhanak, Dashyant
    Edwards, Aled M.
    Frye, Stephen V.
    Gray, Nathanael
    Grimshaw, Charles E.
    Hepworth, David
    Howe, Trevor
    Huber, Kilian V. M.
    Jin, Jian
    Knapp, Stefan
    Kotz, Joanne D.
    Kruger, Ryan G.
    Lowe, Derek
    Mader, Mary M.
    Marsden, Brian
    Mueller-Fahrnow, Anke
    Mueller, Susanne
    O'Hagan, Ronan C.
    Overington, John P.
    Owen, Dafydd R.
    Rosenberg, Saul H.
    Roth, Brian
    Ross, Ruth
    Schapira, Matthieu
    Schreiber, Stuart L.
    Shoichet, Brian
    Sundstrom, Michael
    Superti-Furga, Giulio
    Taunton, Jack
    Toledo-Sherman, Leticia
    Walpole, Chris
    Walters, Michael A.
    Willson, Timothy M.
    [J]. NATURE CHEMICAL BIOLOGY, 2015, 11 (08) : 536 - 541
  • [6] New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays
    Baell, Jonathan B.
    Holloway, Georgina A.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (07) : 2719 - 2740
  • [7] Baker M., 2015, Nature | News
  • [8] Balaram P, 2004, CURR SCI INDIA, V87, P847
  • [9] An open source pharma roadmap
    Balasegaram, Manica
    Kolb, Peter
    Mckew, John
    Menon, Jaykumar
    Olliaro, Piero
    Sablinski, Tomasz
    Thomas, Zakir
    Todd, Matthew H.
    Torreele, Els
    Wilbanks, John
    [J]. PLOS MEDICINE, 2017, 14 (04)
  • [10] Quality guidelines for oral drug candidates: dose, solubility and lipophilicity
    Bayliss, Martin K.
    Butler, James
    Feldman, Paul L.
    Green, Darren V. S.
    Leeson, Paul D.
    Palovich, Michael R.
    Taylor, Anthony J.
    [J]. DRUG DISCOVERY TODAY, 2016, 21 (10) : 1719 - 1727